Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end
of trial. The end of trial is one year after the last patient has entered the study.